General Replicel/Shiseido News

[michaelgranger65]

I have some shares of Replicel and periodically check in to see if there are any updates on their clinical trials and such. Even though the stock is taking a beating right now, the CEO put forth a statement some time ago that offers some clarity on a target date for release in Japan. Check it out:

"A company in transition. RepliCel is transitioning from an early-stage biotech company to one with commercial products.
Today we sit as an early-stage biotech company but one with a rapidly maturing and diversified portfolio of products in development characterized by:
three products in active clinical trials, two of which (RCT-01 & RCS-01) are anticipated to generate clinical data by year-end,
a medical device (RCI-02) in late-stage development which is on-track to be launched to the market in 2017, licensing discussion with major international companies are underway, and
a major international licensing and co-development partnership in place around a product being co-developed with that partner which has the potential to be on the market in Japan in 2018.
2016 promises to be an important year for RepliCel. Over the next 12-15 months, everything we've been working on over the past 36 months has material milestones including:
clinical data from both our RCT-01 (chronic tendon injury) and RCS-01 (aging and sub-damaged skin) clinical trials in late 2016,
Shiseido launching their next-phase clinical trial of RCH-01 (pattern baldness) in Japan in early 2016. This is expected to be approximately a 20-month trial and has the potential to lead to a market launch in 2018 in Japan, and
filing a CE mark application for our dermal injector (RCI-02) seeking permission to sell the device in Europe with label approval for injection of hyaluronic acid-based dermal fillers."

[PayDay]

I think this answers our questions. Really good interview, that explains a lot. I'm cautiously optimistic after hearing this. https://www.baldtruthtalk.com/thread...ecord-Straight

[lacazette]

Hey Lacazette,

Is there anything you'd want to ask the guys at Replicel during the Hair Congress next month?

Hey Hellouser, I do'nt tking about something really particular, but maybe I would want to ask a confirmation that their protocol they are working on is suppose to lead to a high number of de novo hair follicles/ HF neogenesis or if it is more in their mind to save the current hair an miniaturized ones

US army researchers explained that DSC cells can lead to HF neogenesis like DP cells, but maybe it depend on the protocol power/amount of cells, or whatever, so to have a confirmation from them that they work on the real cure would be quite relaxing hehe

Also if Shiseido have changed/enhanced something in the protocol/type of cells they use, for the trial they will enter or if it is exactly the same of replicel phase 1

is there somewhere we can donateł? what's going on with that?

[ShookOnes]

So from phase 1 regrowth was garbage but anyone know if participants lost hair? Freezing hairloss would be a cure asbi just had a 1600 fue..

[hellouser]

Thanks Arieux, it's good to have update


May 2014 Shiseido
opened new cell
-
processing facility; PMDA certified 2015
–
Tech transfer & comparability/validation runs completed 2015
–
Clinical protocol under ASRM (clinical research pathway) currently in review by
MHLW
–
Trial expected to readout late 2017 with potential to predicate a market approval
application


Can't wait for their trial to begin, if 2016, their 2018 market timeline will finally become a real concrete option

Again it's incredible how japan regenerative medecine system is an insane benediction for us, it cut 7/10 years in timeline. just imagine if it doesn't exist o0 we would depressly talk about 2022/2025 as the shorter possibility if everything would go well

Now with japan, any company who would come out with a strong protocol is one phase away for possible marketing ( as they explained the timeline between preclinical and commercialisation now is 2/3 years ( safety phase/prediction efficiency, approval administration, GMP manufacturing), unlike the 7/10 years that would be needed in the old approval system

Hey Lacazette,

Is there anything you'd want to ask the guys at Replicel during the Hair Congress next month?

[lacazette]

Thanks Arieux, it's good to have update


May 2014 Shiseido
opened new cell
-
processing facility; PMDA certified 2015
–
Tech transfer & comparability/validation runs completed 2015
–
Clinical protocol under ASRM (clinical research pathway) currently in review by
MHLW
–
Trial expected to readout late 2017 with potential to predicate a market approval
application


Can't wait for their trial to begin, if 2016, their 2018 market timeline will finally become a real concrete option

Again it's incredible how japan regenerative medecine system is an insane benediction for us, it cut 7/10 years in timeline. just imagine if it doesn't exist o0 we would depressly talk about 2022/2025 as the shorter possibility if everything would go well

Now with japan, any company who would come out with a strong protocol is one phase away for possible marketing ( as they explained the timeline between preclinical and commercialisation now is 2/3 years ( safety phase/prediction efficiency, approval administration, GMP manufacturing), unlike the 7/10 years that would be needed in the old approval system

[Renee]

Their chief medical officer Rolf Hoffman filed a new patent, don't know what that means though!

https://www.google.com/patents/US20150218520?dq=dermal+papilla+cells&hl=en&sa=X&ved=0CB4Q6AEwAGoVChMI7Z-Oou21yAIVTMZjCh2yVQpy

[Sogeking]

This is their updated presentation from Mesa: http://replicel.com/wp-content/uploa...n-Oct-2015.pdf

Note:

they are still aiming for 2018 on the market.Hopefully it will be more effective than Replicel Phase 1.

[TooMuchHairWontKillYou]

Shiiiet now they're saying they will conduct phase 2 in 2015/2016. In 2016 they will say 2016/2017 and so on...

[Arieux]

This is their updated presentation from Mesa: http://replicel.com/wp-content/uploa...n-Oct-2015.pdf

Note:

• Shiseido manufacturing and clinical trial in Japan: (...) Trial expected to readout late 2017 with potential to predicate a market approval
application

[runrunrun]

Guys Replicel updated new PPT files in their facebook homepage.

[brocktherock]

These delays do get annoying but they are literally the only company that has given us news updates, timelines, expectations and answers email questions. I don't think they are just goofing around.

[efedrez]

I'm not sure if it has been published before but replicel answered a question about their phase 2 trial on their facebook page.

"Yes, our phase 2 trial start date has been pushed off many times; however we believe the reasons for us doing so are in the stakeholder’s best interests. When we completed our phase 1 trial it was with the anticipation that we would almost immediately apply to commence a larger phase 2 trial but a significant manufacturing issue that was out of our control conspired to prevent that from happening. GE pulled the growth media off the market that we had always used to grow the dermal sheath cup cells (the basis of RCH-01). When Lonza tried to reproduce the same media it did not work, so we had to go back to the R&D bench and essentially recreate a media that would give us the same product. We tried many different formulas and even after that was accomplished we then had to conduct all the validation runs and testing to gather the data needed to prove to the regulators that it was materially the same product we had tested in phase 1 -- a prerequisite for them to consider an application for a phase 2 trial (rather than having to go back and repeat phase 1). This has taken an incredible amount of work but it is now almost complete. In the meantime, we took advantage of this opportunity to improve other aspects of the manufacturing in order to optimize the product/process robustness, minimize product failures, better define the product specifications, etc. We also began to work on developing other more proprietary media solutions such as serum-free media and animal-free media which we anticipate will add future value to the product. We have also worked on optimizing cell recovery from the original tissue biopsy. In the end, we believe the RCH-01 that we expect to use for next-phase clinical testing both in Japan and Germany is in biologic terms the same product but is a more commercially viable product because of the various process optimizations we conduct. We continuing to invest in manufacturing optimization of RCH-01 and our other cell-based products with the aim of bringing any improvements possible such as abbreviating manufacturing time, increasing cell yield, lowering production costs, etc. With this said, we should be able to file our clinical trial application with German regulators before the end of this year, and expect Shiseido to announce the start of their trial this year as well."

[TooMuchHairWontKillYou]

5 Questions with David Hall

http://www.cantechletter.com/2015/07/5-questions-with-david-hall-of-replicel-life-sciences/

"The regeneration of chronically injured tendon, the natural rejuvenation of the extra-cellular matrix under the dermis of those with aging or sun-damaged skin, and the regrowth of hair for those people suffering from pattern baldness"

[Folliman]

I want to see pictures of the results so bad...